Clinical trial
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease…
NCT00367237 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00367237 |
|---|---|
| Title | Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) |
| Official title | A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Integrated Therapeutics Group Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Psoriatic |
| Intervention type | Drug |
| Interventions | Infliximab + methotrexate (IFX + MTX), Methotrexate (MTX) |
| Enrollment | 115 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 22, 2006 |
| Last update posted | Apr 11, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: